Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development

Taking stock of the drug industry, from the lab to the medicine chest

September 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christopher Capozziello for STAT STAT+ | Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades Kathy Giusti, a cancer survivor, author of "Fatal to Fearless," and a former pharma exec, has raised $600 million for multiple myeloma research. By Matthew Herper STAT+ | Greece's antitrust regulator probes Novartis over practices tied to a pricey eye drug The company directly harmed the country, competitors, as well as consumers and patients, antitrust officials maintained. By Ed Silverman STAT+ | Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition The drug is for cerebral cavernous malformation, a potentially fatal condition that causes brain vessels to become enlarged and irregular By Allison DeAngelis Andrew Joseph/STAT STAT+ | At major cardiology conference, Wegovy's the word The meeting of the European Society of Cardiology was a reminder that researchers are still uncovering ways semaglutide may improve people's health. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser